Tumor necrosis factor inhibitors in psoriatic arthritis

References

• Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545–568.
   PubMed Web of Science ®Google Scholar
• Eder L, Gladman DD. Psoriatic arthritis: phenotypic variance and nosology. Curr Rheumatol Rep. 2013;15:316.
   PubMed Web of Science ®Google Scholar
• Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015 Mar;27(2):118–126.
   PubMed Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005 Mar;64(Suppl 2):ii14–7.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017 Mar 9;376(10):957–970.
   PubMed Web of Science ®Google Scholar
• Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012 May 05;71(8):1267–1272.
   PubMed Web of Science ®Google Scholar
• Jon Love T, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71(8):1273–1277. BMJ Publishing Group Ltd and European League Against Rheumatism.
   PubMed Web of Science ®Google Scholar
• Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009 Feb 15;61(2):233–239.
   PubMed Web of Science ®Google Scholar
• Ciurtin C, Roussou E. Cross-sectional study assessing family members of psoriatic arthritis patients affected by the same disease: differences between Caucasian, south Asian and Afro-Caribbean populations living in the same geographic region. Int J Rheum Dis. 2013 Aug;16(4):418–424.
   PubMed Web of Science ®Google Scholar
• Tey HL, Ee HL, Tan AS, et al. Risk factors associated with having psoriatic arthritis in patients with cutaneous psoriasis. J Dermatol. 2010;37(5):426–430.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Thavaneswaran A, Chandran V, et al. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011 Dec;70(12):2152–2154.
   PubMed Web of Science ®Google Scholar
• Gladman DD. Early psoriatic arthritis. Rheum Dis Clin North Am. 2012;38(2):373–386.
   PubMed Web of Science ®Google Scholar
• Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015 Jun;74(6):1045–1050.
   PubMed Web of Science ®Google Scholar
• Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003 Dec;42(12):1460–1468.
   PubMed Web of Science ®Google Scholar
• Kane D, Pathare S. Early psoriatic arthritis. Rheum Dis Clin North Am. 2005 Nov;31(4):641–657.
   PubMed Web of Science ®Google Scholar
• Geijer M, Lindqvist U, Husmark T, et al. The Swedish early psoriatic arthritis registry 5-year followup: substantial radiographic progression mainly in men with high disease activity and development of dactylitis. J Rheumatol. 2015 Nov;42(11):2110–2117.
   PubMed Web of Science ®Google Scholar
• Kirkham B, De Vlam K, Li W, et al. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial. Clin Exp Rheumatol. 2015 Jan-Feb;33(1):11–19.
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Ramiro S, et al. European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016 March 01;75(3):499–510.
   PubMed Web of Science ®Google Scholar
• Coates LC, Helliwell PS. Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol. 2016 Feb;43(2):356–361.
   PubMed Web of Science ®Google Scholar
• Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012;71(3):319–326. BMJ Publishing Group Ltd and European League Against Rheumatism.
   PubMed Web of Science ®Google Scholar
• Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012 Aug;51(8):1368–1377.
   PubMed Web of Science ®Google Scholar
• Pincus T, Bergman M, Yazici Y. Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis? Clin Exp Rheumatol. 2015;33:S82–93.
   PubMed Web of Science ®Google Scholar
• Lie E, Van Der Heijde D, Uhlig T, et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2010 Apr;69(4):671–676.
   PubMed Web of Science ®Google Scholar
• Mease PJ. Biologic therapy for psoriatic arthritis. Rheum Dis Clin America. 2015 11. 41(4):723–738.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582–591.
   PubMed Web of Science ®Google Scholar
• Inman RD, Davis JC, Heijde DVD, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheumatol. 2008;58(11):3402–3412.
   PubMed Web of Science ®Google Scholar
• Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis. 2014 Jan;73(1):39–47.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–2146.
   PubMed Web of Science ®Google Scholar
• Braun J, Van Der Horst-Bruinsma, Irene E, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum. 2011;63(6):1543–1551.
   PubMed Web of Science ®Google Scholar
• Abrouk M, Nakamura M, Zhu TH, et al. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. J Dermatolog Treat. 2017;18:1–7.
   Google Scholar
• Orbai AM, Ogdie A. Patient-reported outcomes in psoriatic arthritis. Rheum Dis Clin North Am. 2016 May;42(2):265–283.
   PubMed Web of Science ®Google Scholar
• Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 09;72(9):3666–3670.
   PubMed Web of Science ®Google Scholar
• Bradley J. TNF-mediated inflammatory disease. J Pathol. 2008;214(2):149–160.
   PubMed Web of Science ®Google Scholar
• Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717.
   PubMed Web of Science ®Google Scholar
• Van Kuijk AW, Reinders-Blankert P, Smeets TJ, et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006 Dec;65(12):1551–1557.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Gupta SC, Kim JH, Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119(3):651–665. American Society of Hematology.
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–279.
   PubMed Web of Science ®Google Scholar
• Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 1997 Feb 20;385(6618):733–736.
   PubMed Web of Science ®Google Scholar
• Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997 Feb 20;385(6618):729–733.
   PubMed Web of Science ®Google Scholar
• Chan FK, Chun HJ, Zheng L, et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000;288(5475):2351–2354. American Association for the Advancement of Science.
   PubMed Web of Science ®Google Scholar
• Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012;8(11):656–664.
   PubMed Web of Science ®Google Scholar
• Lories RJ, Schett G. Pathophysiology of new bone formation and ankylosis in spondyloarthritis. Rheum Dis Clin North Am. 2012 Aug;38(3):555–567.
   PubMed Web of Science ®Google Scholar
• Croft M, Siegel RM, Beyond TNF. TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol. 2017;13(4):217–233.
   PubMed Web of Science ®Google Scholar
• Coates LC, FitzGerald O, Helliwell PS, et al. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same? Semin Arthritis Rheum. 2016 12;46(3):291–304.
   PubMed Web of Science ®Google Scholar
• De Vlam K, Gottlieb AB, Mease PJ. Current concepts in psoriatic arthritis: pathogenesis and management. Acta Derm Venereol. 2014;94(6):627–637.
   PubMed Web of Science ®Google Scholar
• Lories RJ, McInnes IB. Primed for inflammation: enthesis-resident T cells. Nat Med. 2012;18(7):1018.
   PubMed Web of Science ®Google Scholar
• Ternant D, Bejan-Angoulvant T, Passot C, et al. Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis. Clin Pharmacokinet. 2015;54(11):1107–1123.
   PubMed Web of Science ®Google Scholar
• Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633–659.
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007 Nov;13(11):1323–1332.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang E, Balthasar J. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–558.
   PubMed Web of Science ®Google Scholar
• Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. Biodrugs. 2014;28(1):15–23.
   Web of Science ®Google Scholar
• Zhou HFCP. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol. 2005 May;45(5):490–497.
   PubMed Web of Science ®Google Scholar
• Wong M, Ziring D, Korin Y, et al. TNFα blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008 2;126(2):121–136.
   PubMed Web of Science ®Google Scholar
• Hu S, Liang S, Guo H, et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view. J Biol Chem. 2013 Sep 20;288(38):27059–27067.
   PubMed Web of Science ®Google Scholar
• Ash Z, Emery P. Golimumab – a new tool in the armoury against inflammatory arthritis. Ann Med. 2011 Mar;43(2):133–141.
   PubMed Web of Science ®Google Scholar
• Ferri N, Bellosta S, Baldessin L, et al. Pharmacokinetics interactions of monoclonal antibodies. Pharmacological Res. 2016;9(111):592–599.
   Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004 11;93(11):2645–2668.
   PubMed Web of Science ®Google Scholar
• Levy RA, Guzman R, Castaneda-Hernandez G, et al. Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications. Immunotherapy. 2016 Dec;8(12):1427–1436.
   PubMed Web of Science ®Google Scholar
• Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism. Nature. 1964 Sep 26;203:1352–1354.
   PubMed Web of Science ®Google Scholar
• Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007;47(3):383–396.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Lyn S, Lv Y, et al. Pharmacokinetics and safety of golimumab in healthy Chinese subjects following a single subcutaneous administration in a randomized phase I trial. Clin Drug Investig. 2013;33(11):795–800.
   PubMed Web of Science ®Google Scholar
• Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies. Biodrugs. 2010;24(1):23–39.
   PubMed Web of Science ®Google Scholar
• Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645–660.
   PubMed Web of Science ®Google Scholar
• Dostalek M, Gardner I, Gurbaxani BM, et al. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013 Feb;52(2):83–124.
   PubMed Web of Science ®Google Scholar
• Cimzia (certolizumab) [package insert]. Smyrna, GA: UCB Inc. 2016 [cited 2017 Apr]. Available from: https://www.cimzia.com/assets/pdf/Prescribing_Information.pdf
   Google Scholar
• Remicade (infliximab) [package insert]. Horsham, PA: Janssen Biotech, Inc. 2013 [cited 2017 Apr]. Available from: https://www.remicade.com/shared/product/remicade/prescribing-information.pdf
   Google Scholar
• Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol. 2010;10(3):308–315.
   PubMed Web of Science ®Google Scholar
• Mewar D, Wilson AG. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol. 2011;162(4):785–791.
   PubMed Web of Science ®Google Scholar
• Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum. 2005 4. 34(5, Supplement 1):12–18.
   PubMed Web of Science ®Google Scholar
• Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother. 2000 Feb;34(2):161–164.
   PubMed Web of Science ®Google Scholar
• Enbrel (etanercept) [package insert]. Thousand Oaks, CA: Immunex Corporation. 2016 [cited 2017 Apr]. Available from: http://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/enbrel/enbrel_pi.ashx
   Google Scholar
• Humira (adalimumab) [package insert]. North Chicago, IL: AbbVie Inc. 2016 [cited 2017 Apr]. Available from: http://www.rxabbvie.com/pdf/humira.pdf
   Google Scholar
• Simponi (golimumab) [package insert]. Horsham, PA: Janssen Biotech; 2013 [cited 2017 Apr]. Available from https://www.simponihcp.com/shared/product/simponi/prescribing-information.pdf
   Google Scholar
• Passot C, Mulleman D, Bejan-Angoulvant T, et al. The underlying inflammatory chronic disease influences infliximab pharmacokinetics. Mabs. 2016 Oct;8(7):1407–1416.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(2):353–363.
   PubMed Web of Science ®Google Scholar
• Xu Z, Vu T, Lee H, et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-α human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009;49(9):1056–1070.
   PubMed Web of Science ®Google Scholar
• Hojgaard P, Glintborg B, Kristensen LE, et al. The influence of obesity on response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford). 2016 Dec;55(12):2191–2199.
   PubMed Web of Science ®Google Scholar
• Di Minno MN, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor alpha blockers. Ann Rheum Dis. 2014 Jun;73(6):1157–1162.
   PubMed Web of Science ®Google Scholar
• Gill KL, Machavaram KK, Rose RH, et al. Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics. Clin Pharmacokinet. 2016;55(7):789–805.
   PubMed Web of Science ®Google Scholar
• Plasencia C, Pascual-Salcedo D, Nuño L, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012;71(12):1955–1960. BMJ Publishing Group Ltd and European League Against Rheumatism.
   PubMed Web of Science ®Google Scholar
• Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24(11):1720–1740.
   PubMed Web of Science ®Google Scholar
• Thomas SS, Borazan N, Barroso N, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. Biodrugs. 2015 Aug;29(4):241–258.
   PubMed Web of Science ®Google Scholar
• Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013 Dec;72(12):1947–1955.
   PubMed Web of Science ®Google Scholar
• Van Kuijk AW, De Groot M, Stapel SO, et al. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis. 2010;69(3):624–625.
   PubMed Web of Science ®Google Scholar
• Vogelzang EH, Kneepkens EL, Nurmohamed MT, et al. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis. 2014;73:2178–2182. BMJ Publishing Group Ltd and European League Against Rheumatism.
   PubMed Web of Science ®Google Scholar
• Zisapel M, Zisman D, Madar-Balakirski N, et al. Prevalence of TNF-alpha blocker immunogenicity in psoriatic arthritis. J Rheumatol. 2015 Jan;42(1):73–78.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007;66(4):498–505. BMJ Publishing Group Ltd and European League Against Rheumatism.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Van Der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64(8):2504–2517.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009 Apr;60(4):976–986.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014. BMJ Publishing Group Ltd and European League Against Rheumatism.
   Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279–3289.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2013. BMJ Publishing Group Ltd and European League Against Rheumatism. .
   Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264–2272.
   PubMed Web of Science ®Google Scholar
• Vogelzang EH, Pouw MF, Nurmohamed M, et al. Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs. Ann Rheum Dis. 2015;74(2):474–475. BMJ Publishing Group Ltd and European League Against Rheumatism.
   PubMed Web of Science ®Google Scholar
• Mease P, Deodhar A, Fleischmann R, et al. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open. 2015;1(1). EULAR.
   Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Antoni CE, Gladman D. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65:1038.
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, De Vlam K. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum. 2007;56(8):2698–2707.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. The Lancet. 2000;356(9227):385–390.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006 Apr;33(4):712–721.
   PubMed Web of Science ®Google Scholar
• Schafer P, Parton A, Gandhi A, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–855.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014 Jun;73(6):1020–1026.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Myerson GE, Fleischmann RM, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016 Sep;43(9):1724–1734.
   PubMed Web of Science ®Google Scholar
• Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016 Jun;75(6):1065–1073.
   PubMed Web of Science ®Google Scholar
• Wells AF, Edwards CJ, Adebajo AO, et al. Apremilast in the treatment of DMARD-naive psoriatic arthritis patients: results of a phase 3 randomized, controlled trial (PALACE 4). 2013 ACR/ARHP Annual Meeting; Abstract L4.
   Google Scholar
• Pathan E, Abraham S, Van Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis. 2013;72(9):1475–1480. BMJ Publishing Group Ltd and European League Against Rheumatism.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Study of apremilast to treat subjects with active ankylosing spondylitis (POSTURE); 2017 [cited 2017 May 3]. Available from https://www.clinicaltrials.gov/ct2/show/results/NCT01583374?term=apremilast&cond=ankylosing+spondylitis&rank=2&sect=X37016#limit
   Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015 Oct;373(14):1329–1339.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2015 9 19–25;386(9999):1137–1146.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. The Lancet. 2013;382(9894):780–789.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Puig L, Gottlieb AB, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res. 2015;67(12):1739–1749.
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–999. BMJ Publishing Group Ltd and European League Against Rheumatism.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73(6):1000–1006. BMJ Publishing Group Ltd and European League Against Rheumatism.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015 Dec 24;373(26):2534–2548.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study to evaluate the efficacy and safety of ustekinumab in the treatment of anti-TNF (alpha) refractory participants with active radiographic axial spondyloarthritis.; 2017 [cited 2017 May 3]. Available from https://www.clinicaltrials.gov/ct2/show/record/NCT02438787?term=ustekinumab&rank=31
   Google Scholar
• ClinicalTrials.gov. A study to evaluate the efficacy and safety of ustekinumab in the treatment of anti-TNFα naïve participants with active radiographic axial spondyloarthritis; 2017 [cited 2017 May 3]. Available from https://www.clinicaltrials.gov/ct2/show/record/NCT02437162?term=ustekinumab&rank=32
   Google Scholar
• Ungprasert P, Thongprayoon C, Davis III JM. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: a meta-analysis. Semin Arthritis Rheum. 2016;45(4):428–438.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Thongprayoon C, Davis III JM. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis. Clin Rheumatol. 2016;35(7):1795–1803.
   PubMed Web of Science ®Google Scholar
• Fagerli KM, Lie E, Van Der Heijde D, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis. 2014 Jan;73(1):132–137.
   PubMed Web of Science ®Google Scholar
• Behrens F, Canete JD, Olivieri I, et al. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature (provisional abstract). SO: Database of Abstracts of Reviews of Effects; 2014.
   Google Scholar
• Chingcuanco F, Segal JB, Kim SC, et al. Bioequivalence of biosimilar tumor necrosis factor-alpha inhibitors compared with their reference biologics: a systematic review. Ann Intern Med. 2016 Oct 18;165(8):565–574.
   PubMed Web of Science ®Google Scholar
• Cohen S, Kay J. Biosimilars: implications for rheumatoid arthritis therapy. Curr Opin Rheumatol. 2017;29(3):260–268.
   PubMed Web of Science ®Google Scholar
• Emery P, Vencovsky J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017 Jan;76(1):51–57.
   PubMed Web of Science ®Google Scholar
• Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017 Feb;76(2):346–354.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017 Feb;76(2):355–363.
   PubMed Web of Science ®Google Scholar